Published studies on the use of stereotactic radiotherapy for dogs with pituitary tumors are There was no statistical difference in median overall survival for different protocols. Patients with nonfunctional masses had longer median overall survival than those with hyperadrenocorticism (P = 0.0003). Survival outcomes with stereotactic radiotherapy were shorter than those previously reported with definitive radiation, especially for dogs with hyperadrenocorticism.
INTRODUCTION
Clinically, dogs with pituitary masses may present with endocrine disease and/or intracranial neurological signs. The most common neurological signs are behavior changes, obtundation, aggressiveness, anisocoria, loss of vision, and seizures. 1 Both definitive and palliative radiation therapy have been used in dogs with pituitary masses, with a reported 2-year survival rate of 87% with definitive radiation. [1] [2] [3] [4] [5] [6] [7] [8] [9] These brain radiation therapy protocols involve either weeks of treatments and/or large regions of normal brain receiving high radiation dose, total doses of 45-54 Gray (Gy) with 2.5-3 Gy given in multiple fractions, or palliative protocols with weekly doses of 5-9 Gy. [10] [11] [12] [13] [14] Although chemotherapy has been used with some intracranial tumors, a survival benefit has not clearly been demonstrated, including for pituitary masses. 15, 16 The potential benefits of stereotactic radiotherapy for a variety of intracranial tumor types in dogs have previously been described, but pituitary tumors have accounted for very few stereotactic radiotherapy patients in the literature. [16] [17] [18] [19] [20] [21] [22] Stereotactic radiotherapy utilizes high radiation doses in 1-5 fractions, and normal tissues are typically spared by avoidance rather than fractionation. 23, 24 Stereotactic radiotherapy delivers an ablative dose, and this type of administration is achievable by use of combined immobilization, image-guidance, and advanced computer radiation planning systems that create the highly conformal dose. 23, 24 Intracranial tumors are ideal candidates for stereotactic radiotherapy because they are often small and well-defined malignancies on imaging, and steep dose gradients can be achieved to minimize the irradiated brain volume and allow for higher dose per fraction. 19 Stereotactic radiotherapy can be delivered with a linear accelerator via a multi-leaf collimator system, either with IMRT or three-dimensional-conformal fields, or with a cone-based system for beam collimation. 17, 18, 25 There is one study of 51 dogs with various intracranial tumors that received stereotactic radiotherapy treatment. In this stereotactic radiotherapy study, four dogs had pituitary masses and received a median dose of 16.25 Gy (range 15 -25 Gy), with a median survival of 118 days. 20 Stereotactic radiotherapy was also used in another study that included three dogs with pituitary masses; they received 24 Gy in three fractions of 8 Gy every other day, and they had survival times ranging from 255 to 342 days. 21 The goal of this study was to assess survival in a larger group of dogs receiving stereotactic radiotherapy for suspected pituitary tumors with two different stereotactic radiotherapy protocols on two different radiotherapy platforms. A secondary goal was to assess what clinical and radiation variables correlate with survival in this study group.
METHODS
This study was a retrospective observational study of medical records Cushing's disease, diagnostic testing and/or previous medical management was not an inclusion criterion. Radiation treatment parameters, follow-up visit information, and survival times were also recorded.
Patients were assigned into one of three categories for analyses: (1) nonfunctional tumors (those having no clinical signs nor testing consistent with Cushing's disease), (2) functional tumors having Cushing's disease (having classic signs of Cushing's that included polyuria and polydipsia), or (3) functional tumors having atypical Cushing's disease (having an low dose dexamethasone suppression test consistent with Cushing's, but without classic signs of the disease).
Initial diagnostic images were obtained from referring facilities using CT or MRI without standardized protocols. As part of the inclusion criteria for the current study, all cases had a standardized simulation CT scan prior to stereotactic radiotherapy at the UC Davis referral hospital. The scan was acquired with a helical CT scanner (Prospeed General Electric Co., Milwaukee, WI or Lightspeed 16 General Electric Co., Milwaukee, WI). Patients were positioned as previously described with either a stereotactic target positioner box for one treatment planning system (BrainLab AG System, Feldkirchen, Germany) or with three crosshairs drawn directly onto the positioning mask for a second treatment planning system (Eclipse system, Varian, Palo Alto, CA). 18, 26 A noncontrast CT with 120 kV and 150 mA with 0.625-1 mm collimation was performed. Contrast-enhanced images with 1 mm collimation were acquired with iodinated contrast medium (Iopamidol, 370 mg I/mL, Bracco Diagnostics Inc., Princeton, NJ) at a dose of 740 mg I/kg. The scans encompassed the entire skull, and the field of view included the positioning frame for noncontrast images.
All CT images were imported into one of the two treatment planning systems (cone-based planning = Iplan version 4.1, BrainLab, Munich, Germany; and three-dimensional-conformal or IMRT planning = Eclipse v. 11, Palo Alto, CA) as previously described, and fused with magnetic resonance images if available. 18, 26, 27 Relevant target volumes were contoured, including the gross tumor volume, clinical target volume, and planning target volume by the attending radiation oncologist recommendations. The relevant organs at risk were contoured, including the brain, brain minus planning target volume (region of brain not included in the planning target volume), brainstem, eyes, optic chiasm, and inner ears based on clinician preferences for plan optimization. Radiation plans were derived with a definitive intent for treatment. Treatment plans were evaluated based on dose-volume histogram coverage of the planning target volume and dose to the normal organs at risk based on radiation oncologist decisions. When possible, radiation oncologists attempted to have 90-95% of the planning target volume covered by the prescription dose while keeping dose to the adjacent organs at risk as low as reasonably achievable, but standardized organ at risk constraints were not in place. All plans were assessed by either film (FilmQA, Ashland, Covington, KY) and chamber dose measurement (A16 microchamber, Standard Imaging, Middleton, WI) as previously described, or with a quality assurance system (Mapcheck, Sun Nuclear Corporation, Melbourne, FL) using standard quality assurance techniques, with acceptable gamma error analysis of 3% dose difference and 3 mm distance to agreement with at least 95% of measured points passing. 18 For treatment setup with cone-based planning cases, two orthogonal-view digitally reconstructed radiographs were created for each planned isocenter such that a double exposure digital port film (4 × 4 cm double exposed region overlying the open port film) around the treatment isocenter at 0 o (dorsal port) and 90 o (patient lateral port) could be utilized for image comparison on treatment days, and the target positioning box was used as previously described. 18 For three-dimensional-conformal/IMRT cases using the TrueBeam linear accelerator, CBCT scans were acquired on treatment days and matched digitally to the diagnostic CT images used for treatment planning to match the isocenters. The couch adjustments were automatically registered through the TrueBeam software, and couch shifts were made after clinical approval of the imaging match by the attending radiation oncologist. Once in the correct position, the dog was treated. All dogs were treated with 6 MV photons delivered by a linear accelerator (Clinac or Truebeam).
All dogs were placed on approximately 0.5 mg/kg per os daily prednisone prior to or on the first treatment day. The dogs had follow-up visits 2 weeks after radiation, then phone calls or follow-up visits were performed every 2 weeks thereafter, with 20-50% reductions in prednisone dose at each contact until the dogs were no longer on prednisone, as long as the dogs were doing well at home. The dogs were followed either with phone calls or recheck visits until death or until last contact prior to publication submission. Information including side effects seen within 16 weeks after radiation, which were considered acute side effects, and also long-term clinical signs, possible long-term adverse events, and survival were noted. Tumor height and brain height were measured on the post-contrast CT image slice on which the tumor was the largest using the measuring tool. 1 The various volumes used in the study for tumor and brain were measured using the volume measuring tool in the planning systems. 28 The gross tumor volume:brain volume and planning target volume:brain volume were then calculated.
All graphs and statistical analyses were made by use of commer- weight loss, and poor appetite. To look for estimated differences in survival between categorical variables, a log rank test was used. To look for differences in survival times for continuous variables, a Cox regression with a Breslow method for ties was done. A P-value < 0.05 was considered statistically significant. (14) ). There was one female intact dog that was Cushingoid and treated with a single fraction using cone-based planning. A total of 22 dogs were male neutered (Cushing's (12), nonfunctional (10); three fraction (8) , one fraction (14) ; conformal/IMRT plan (8), cone-based plan (14) ). There were four male intact dogs ((Cushing's (1), nonfunctional (3); three fraction (2), one fraction (2); threedimensional-conformal/IMRT plan (2), cone-based plan (2)). The other patient population description details are shown in Table 1 . There was no statistical difference in age or weight based on fractionation scheme (two sample t-test, P = 0.16 for age; two-sample Wilcoxon rank-sum, Notes. a One patient received 8 Gy × 3 doses every other day and was not included in protocol-specific survival analysis. b Neurological signs included behavior change (n = 13), pacing, circling or head pressing (n = 12), tremors (n = 9), obtundation (n = 7), ataxia (n = 7), apparent weakness (n = 4), spacing out/staring at walls (n = 4), seizures (n = 3), and blindness (n = 2).
RESULTS
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TA B L E 1 Patient population description
A total of 27 cases were diagnosed with classic Cushing's and two cases, primarily due to differences in portal imaging on the linear accelerator used for the cone-based cases vs. CBCT imaging used on three-dimensional-conformal/IMRT cases ( Figure 1A-B) . 26, 29, 30 Peritumoral edema was not included in the target volume for any case.
Patients were treated with the cone-based system until October 2013 and were treated with the three-dimensional-conformal/IMRT system after that time. Additionally, patients were treated with a single 15 Gy fraction on the cone-based system with a Clinac 2100C, and with 8 Gy × 3 fractions with the three-dimensionalconformal/IMRT and Truebeam system (Clinac 2100C or TrueBeam, Varian Medical Systems, Palo Alto, CA). For cone-based treatment plans, a radiation plan was created using one or more isocenters with varying numbers and lengths of arcs using a cone-based system. When more than one isocenter or more than one arc were used, the isocenters and arcs were differently weighted to optimize the radiation dose distribution in the target volume and minimize radiation exposure to organs at risk. For three-dimensionalconformal/IMRT treatment plans, a radiation plan was created using 11-12 fields with a single isocenter. Either intensity modulated In total, 31 dogs were treated with one system (Clinac 2100C, Varian, Palo Alto, CA) with a tertiary small field collimator cone set (StereoPlan, Mill Creek, WA) and 14 dogs were treated with a second system (TrueBeam Linac, Varian, Palo Alto, CA) with high-definition multi-leaf collimator (1 fraction: Cushing's n = 20, non-functional masses n = 11; 3 fraction: Cushing's n = 9, non-functional masses n = 3). The treatment and brain volumes are described in Table 2 . The doses to the planning target volume are described in Table 3 Plan normalization was based on limiting the dose to normal organs at risk, and most plans had at least 90-95% of the target volume receiving prescription dose. patient deaths (one suspected anesthetic death and one suspected death due to pulmonary thromboembolism), and no other immediate adverse effects were noted.
All images acquired before and after treatment were interpreted by a single veterinary radiologist. The recorded CT imaging characteristics were as follows: all masses were isoattenuating to hyperattenuating on noncontrast images and hyperattenuating on contrastenhanced images. A total of 18 cases showed cystic structures, and nine cases showed mineralization. One case had CT imaging characteristics considered to be consistent with perilesional edema and one case had characteristics suggestive of intratumoral hemorrhage.
Ten dogs had follow-up imaging approximately 3 months and 6 months after stereotactic radiotherapy treatment as part of another, previously published study. 35 All re-imaged dogs were treated with the single fraction protocol because the imaging grant was funded dur- improvement by the 2-week recheck visit, the remainder took 1 month or more for a clinical benefit to be noted). Improvement in Cushing's signs or management was reported in nine cases after radiation, while 12 cases reported no improvement in Cushing's signs during the postradiation period, and the remaining records did not have data reported on Cushing's control. In many cases with reported improvement in Cushing's signs, a timeline for improvement was not clearly defined in the record. Improvement in neurological signs were noted in the record at some point after radiation treatment for the 27/33 cases with pretreatment neurological signs. However, details on concurrent prednisone administration and tapering were variable.
Five dogs were euthanized in part due to worsening hyperadrenocorticism signs despite medical and radiation treatment 124-582 days after treatment. Four of these dogs were treated with a single fraction using cone-based software, while one was treated with three fractions using three-dimensional-conformal/IMRT. Twenty-three dogs were euthanized 104-1028 days after treatment, in part due to worsening neurological signs. Seventeen of these dogs were treated with a single fraction using cone-based software, while six were treated with three fractions using three-dimensional-conformal/IMRT. Nine dogs were euthanized for unknown reasons, but were included as dead of disease in analysis. Two dogs were euthanized due to hypernatremia that occurred 109 and 148 days after treatment, one treated with the single fraction protocol using cone-based planning, and one treated with three fractions of 8 Gy using three-dimensional-conformal/IMRT. 
DISCUSSION
This study demonstrates that cone-based and multi-leaf collimatorbased (either IMRT or three-dimensional-conformal field) stereotactic radiotherapy are feasible treatment options for suspected pituitary tumors in dogs with a median overall survival of 311 days. There were few potential acute adverse effects that were generally transient and/or responsive to steroid adjustment, and long-term or late effects may occur but are not well defined in this cohort. Lesion characteristics in this study were consistent with the previously reported information on suspected pituitary tumors. However, it is not possible to conclude whether the dogs in this study had a particular subgroup of pituitary tumors such as adenomas vs. carcinomas, and necropsy was not available for most dogs. Given that biopsy access is difficult in this location, owners often decline biopsy.
Historically, two to four conformal fields were used for canine brain tumors treated with radiation with some cases receiving whole brain radiation and others receiving a 4 × 4 cm field for treatment. 12, 14 Larger planning target volumes are often employed when using limited field numbers and imaging capabilities. Stereotactic radiotherapy limits normal tissue dose, in part by use of advanced on-board imaging and reliable positioning for patients, and also by use of advanced planning systems. 26, 27, [36] [37] [38] [39] [40] To the authors' knowledge, there are only two peer-reviewed veterinary studies that describe stereotactic radiotherapy for very few canine pituitary cases. 20, 21 In one study, four dogs received a median dose of 16.25 Gy and had a median survival of 118 days. 20 This small group of dogs had a shorter survival than is reported in the literature for definitive radiation of pituitary masses, which is similar to our findings. In the other study, three dogs received 24 Gy in three fractions and had survivals ranging from 25 to 342 days; however, only one of the three patients was reported to die of tumor-related causes, and that dog had clinical progression after 189 days. 20 In our study, there was no difference in outcome based on the one-fraction vs. three-fraction protocol. Although the use of Biological Equivalent Dose calculations for stereotactic radiation is controversial, the tumor biologically effective dose for 24 Gy in three fractions (BED 10 43.2, BED 3 88) is higher than the biologically effective dose for 15 Gy in a single fraction (BED 10 37.5, BED 3 90). 41 One might expect the more fractionated protocol to result in higher tumor cell kill, but we did not see a difference in our treatment groups strictly based on protocol. There was also a transition to the Eclipse planning system and the Truebeam system with CBCT at the time of the protocol transition, which also may make any difference that was strictly due to treatment protocol less clear.
In the current study dog population, stereotactic radiotherapy appeared to offer an initial clinical benefit in most dogs (37/45 dogs); although, as seen in the small number of previously published cases, the stereotactic radiotherapy survivals may in fact be shorter than those seen with definitive radiation studies. Additionally, all dogs with demonstrated tumor reduction on repeat imaging had clinical improvement consistent with reduction in their tumor size (nine of 10 had neurological signs at diagnosis, the remaining case was Cushingoid).
Of the cases with neurological signs at the time of treatment, 27/33 reported neurological improvement by the owner or clinician at some point after starting radiation. However, because prednisone was administered at the same time, it is very difficult to assess how much radiation vs. prednisone contributed to the clinical improvement.
The records were not always clear as to when prednisone was stopped, making it further unclear which cases were more likely benefiting from radiation neurologically. A prospective, randomized study comparing stereotactic radiotherapy and definitive radiation would help elucidate the difference in outcomes.
There may be several reasons for the difference in outcomes between historical definitively treated cases and our current stereotactic radiotherapy cases. First, the method of calculating survival varies between publications; for example, a 2007 publication regarding definitive radiation in comparison to control patients calculated survival from imaging diagnosis until death. 1 Our study calculates from the first radiation treatment day until death, which may be a more conservative estimate of survival depending on the delay between imaging and treatment (up to 14 days in our study; not reported in the 2007 study). It is also possible that there is a case selection bias with stereotactic radiotherapy, and sicker patients may now be pursuing stereotactic radiotherapy than would otherwise pursue a radiation intervention due to the shorter treatment course. One might expect to see this bias across all brain tumor types if it is the main cause of the difference; it is notable that excellent outcomes were seen with meningioma cases in a recent stereotactic radiotherapy study that compared favorably to past definitive radiation studies. 17 We noted that there was a difference in target dose variability between the IMRT or three-dimensional-conformal plans versus the cone-based plans. This finding is expected because target dose variability is generally larger for cone-based planning. 42,43 D2 and D98 values may better represent dose heterogeneity than point doses, but these values were only available for three-dimensionalconformal/IMRT plans. As noted, the D2 and D98 values showed relatively low dose variability. Three-dimensional-conformal/IMRT plans had smaller mean and median conformity index values consistent with IMRT and three-dimensional-conformal planning, while median and mean gradient index values were smaller for cone-based plans, consistent with the sharp dose fall-off seen with cone-based planning.
As noted there was no statistical difference between cases treated with a particular linear accelerator, planning method, or fractionation method.
Stereotactic methods have become a good alternative for human patients who are poor surgical candidates due to high control rates and relatively high rates of remission for Cushing's cases compared to definitive radiation, and with similar stereotactic fractionation schemes as in veterinary medicine. [44] [45] [46] It is interesting that the canine cases in our study appeared to have shorter survivals than with conventional fractionated radiation in the dog. It is important to note that direct comparisons to historical studies is challenging due to the small overall numbers of dogs receiving different treatments with different imaging and delivery equipment, and sometimes with different survival calculation methods. Additionally, when comparing human and veterinary literature, it is not clear whether a difference in biology between the two species, difference in sensitivity of tumor cells, or potentially the difference in delivery may partially contribute as some previous studies in humans have used gamma knife while IMRT is more commonly being implemented in veterinary cases.
Additionally the response seen in humans may occur over a decade, which is a very different timeline when compared to the assessed time period for most veterinary studies. It is notable that previous human studies have shown benefits for both functional and nonfunctional pituitary tumors in terms of neurological improvement, yet the PDH control is still variable. 1 In our study, several cases did not have data reported on whether the Cushing's signs improved, while nine reported improvement after radiation and 12 did not have improvement. The exact timeline for improvement was not well documented in the records. Given that at least some of the cases were referred for radiation prior to attempting medical treatment (8) or due to poor control (4), it is important to note at least 12/29 Cushing's cases did not report improvement in their signs, so potentially there were even more cases without improvement in Cushing's signs. Overall it is possible that some cases experienced improvement in their Cushing's management strictly from radiation, but the degree that radiation and medications contributed is not easily clarified in this population.
Therefore, radiation may not be a reliably effective way to control clinical signs of Cushing's disease in functional tumors. 2, 8 Interestingly, a small number of patients developed hypernatremia after treatment. These patients developed restlessness and decreased mentation related to the hypernatremia. It is possible that these patients develop hypernatremia related to lack of water intake, for example, as with adipsic central diabetes insipidus. 47 These patients may also have damage to their hypothalamus from the tumor or radiation itself, resulting in damage to osmoreceptors. 48 It is possible that the radiation damage to the tumor, the tumor itself, or radiation damage to the normal tissue resulted in an altered osmostat, or set-point, in these cases resulting in elevated sodium values and consequential neurological deterioration. In contrast, hyponatremia is a noted complication of radiation in humans, but it is possible that the dogs in our study did not live long enough in many cases to experience this side effect. 44 There are only a small number of cases here, and thus broad conclusions cannot be made.
It is important to note that the expedient stereotactic radiotherapy protocols remain an attractive option for owners despite potential differences in pituitary case outcomes with definitive vs. stereotactic radiotherapy techniques. Additionally, a risk-benefit analysis also must be considered for the anesthetic risk of multiple fractions vs. only one to three fractions of treatment. There are an increasing number of veterinary centers for stereotactic radiation, but there are still very limited total locations for these treatments in the United States, Canada, and Europe. 49 It is important to note that there are many three-dimensional-conformal-capable machines available in veterinary medicine, and depending on imaging capabilities, positioning devices, physicist availability, and machine tolerances, threedimensional-conformal planning can be a useful technique for stereotactic radiotherapy. 25 Because stereotactic radiotherapy delivers high doses of radiation to the tumor, it is imperative to minimize the planning target volume required for treatment to reduce unnecessary dose to neighboring tissues. With the Clinac 2100C and MV imaging, we chose a planning target volume of 2 mm 3 due to the minimal expected intrafraction motion of the cranial and intracranial structures with the BrainLab positioning system. 26 Target location is known with greater certainty using on-board CBCT imaging, so no planning target volume target expansion was used for the TrueBeam system given the well-delineated characteristics of pituitary masses on imaging. 50 Advanced imaging, along with positioning devices and advanced planning systems, are a critical part of reducing the planning target volume for stereotactic radiotherapy cases and minimizing errors in treatment. 27, 37, 51, 52 However, even with image guidance, narrow or no planning target volume expansion may lead to higher risk for geographic misses, especially for treatments with high dose gradients such as stereotactic radiotherapy.
The doses delivered to the normal tissues appeared to be acceptable in this population, albeit with limited follow-up information, with mean doses to the brain under 6 Gy and the brainstem under 2 Gy. The maximum point doses to these regions include regions of the planning target volume (brain minus planning target volume was only contoured in a few cases), and these regions could be at higher risk for necrosis, although necropsies were not available for patients to assess any pathological changes due to radiation.
Interestingly, the doses to the chiasm, which were reported for 13 cases, were notably high with a mean dose of 12.43 Gy in mostly singlefraction cases. Only one case that was blind prior to radiation had their chiasm contoured: a mean chiasm dose of 15.61 Gy and a maximum dose of 16.32 Gy was delivered for this patient. Presumably the chiasm doses were similarly high in the cases without chiasm data available, because of the location of pituitary masses in relation to the chiasm. Only two patients were noted to be blind 4 months or more after stereotactic radiotherapy treatment that did not originally have any visual aberrations prior to radiation, and the chiasm was not contoured in these cases, so, no radiation dose information was reported. It is not clear whether tumor progression vs. radiation ultimately contributed to their vision loss. In humans, single fraction doses greater than 12 Gy result in vision loss risks, but we did not detect a high rate of vision loss in our patients. 53 Bilateral vision loss may be expected with high-dose chiasm irradiation as used here; however, partial vision field loss can instead occur 53 and was not assessed for in the present study.
Limited follow-up, and the fact that the chiasm was contoured in only a subset of cases, also limits our conclusions on chiasm dose. Finally, it is difficult to fully define late radiation effects in this population; however, new blindness (2), hypernatremia (2), and progressive neurological signs (31) could be attributed either to tumor progression or to late radiation effects.
There are limitations to this study. There was no control group to indicate the course of disease in untreated dogs with pituitary tumors and similar neurological statuses. Additionally, lack of necropsy information on the dogs makes it difficult to fully assess whether tumor regrowth or late radiation side effects occurred, or a histological diagnosis as to which tumor type was being treated. It is possible that some tumors were carcinomas, meningiomas, or round cell tumors. Further, MRI or CT imaging of all dogs at multiple time points after receiving radiation would be ideal to fully assess the course of tumor response. Including dogs with both endocrine and non-endocrine disease also limits the study, as summarizing data from both groups may not reveal the true expected survival for either group.
Additionally, endocrine disease is historically less impacted by radiation than neurological disease. 1, 7 The severity of clinical signs was also not assessed in this study, and the severity of Cushing's signs or neurological signs may impact referral for treatment, owner desire to pursue treatment, and ultimately survival. Moreover, the use of different protocols, treatment planning approaches and delivery techniques limits the study as well. Finally, lack of statistical differences between some groups could be due to low power with this relatively small number of cases.
In conclusion, cone-based, IMRT-based, and three-dimensionalconformal stereotactic radiotherapy planning appear to be treatment options for suspected pituitary tumor cases that result in clinical improvement, although short-term and late-term side effects cannot be ruled out in those that had acute signs and/or progressive neurological signs at the time of death. Further assessment of stereotactic radiotherapy techniques for intracranial tumors is warranted, and fractionation may need to be altered in order to achieve survival times seen with traditional fractionated radiotherapy techniques. The outcomes seen with non-functional tumors are superior to those seen with functional tumors in this study, although both groups have shorter survival times than those reported with traditional fractionated radiation. 
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